Synta prices offering to raise $28.6M; J&J halts antibiotic trial after deaths;

@FierceBiotech: "Out of the box, Watson has the knowledge of a first-year medical resident." - IBM's Saxena, manager of Watson program. Article | Follow @FierceBiotech

@JohnCFierce: Bloomberg piece makes spike in drug approvals a sign of underlying shift; Really? I'm not so sure. More | Follow @JohnCFierce

@RyanMFierce: BioDelivery Sciences ($BDSI) grabbed $30M upfront from Endo Pharma for license to pain drug. Release | Follow @RyanMFierce

@FierceMedDev: BBC News: Headache sufferer 'abandoned' after electrode treatment. Story | Follow @FierceMedDev

@MaureenFierce: J&J AIDS vaccine helps protect monkeys from virus in study. Item | Follow @MaureenFierce

> Canadian drug developer AEterna Zentaris ($AEZS) has inked a collaboration deal with Roche's Ventana Medical Systems to develop a companion diagnostic to be used with AEterna Zentaris' doxorubicin LHRH targeted conjugate compound, AEZS-108. Item

> Synta Pharmaceuticals ($SNTA) has priced 7 million shares of common stock at $4.40 per share in a public offering expected to bring in $28.6 million after expenses, the Lexington, MA-based drug developer announced Friday. Release

> Johnson & Johnson ($JNJ) slammed the brakes on a trial for its approved antibiotic Doribax after the deaths of pneumonia patients who got the drug. Report

> Derek Lowe questions some of the common beliefs about clinical attrition rates in drug development on his In the Pipeline blog. Item

> Biotech startup Civitas has reported upbeat results of its Phase I trial of CVT-301, an inhaled version of L-Dopa for treating Parkinson's disease. Article

Pharma News

@FiercePharma: Watson CEO does about-face, says Pfizer won't keep 40% of Lipitor market. $PFE's share was 41% on Dec. 24--Bloomberg. | Follow @FiercePharma

> Bloomberg: J&J's Risperdal settlement to top $1B. More

> Docs demand Hospira action on execution drug. Story

> Novartis plant's quality control understaffed, inadequately trained, FDA says. Article

> Pfizer's Lipitor promos won't keep share up, Watson CEO says. Piece

> Analysts tap Amgen, Celgene as potential 2012 dealmakers. Report

And Finally... Spy games involving the U.S. and China have entered outer space, according to news reports. Item

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.